We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: breast cancer
MedXY News
EnglishTag

breast cancer

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Proteomic and Metabolomic Insights into Cardiac Remodeling in Breast Cancer Patients Undergoing Cardiotoxic Therapy
CardiologyCardiotoxicitymetabolomics

Proteomic and Metabolomic Insights into Cardiac Remodeling in Breast Cancer Patients Undergoing Cardiotoxic Therapy

By MedXY|Sep 19, 2026

This study identifies novel proteomic and metabolomic biomarkers linked to cardiac dysfunction and remodeling in breast cancer patients treated with cardiotoxic therapies, revealing potential pathways for early detection and intervention.

Enhancing Intraoperative Margin Assessment in Early-Stage Breast Cancer with Specimen PET-CT Imaging: Insights from the BrIMA Trial
newsbreast cancer
Breast-Conserving Surgery

Enhancing Intraoperative Margin Assessment in Early-Stage Breast Cancer with Specimen PET-CT Imaging: Insights from the BrIMA Trial

By MedXY|Jul 15, 2026

The BrIMA trial demonstrates that specimen PET-CT imaging significantly improves intraoperative detection of positive margins during breast-conserving surgery for early-stage breast cancer, reducing re-excision rates and enhancing surgical

Cardiac Risk After Heart-Sparing Breast Radiotherapy: Emphasis on Left Anterior Descending Artery Dose Metrics
Cardiologybreast cancerCardiotoxicity

Cardiac Risk After Heart-Sparing Breast Radiotherapy: Emphasis on Left Anterior Descending Artery Dose Metrics

By MedXY|Jul 2, 2026

Emerging evidence indicates that radiation dose to the left anterior descending coronary artery better predicts cardiac events than whole-heart dose in breast radiotherapy, emphasizing the importance of LAD-based planning to reduce long-ter

GLP-1 Receptor Agonists May Outperform Bariatric Surgery for Breast Cancer Outcomes in Obese Postmenopausal Women
Diabetes & Endocrinologybariatric surgerybreast cancer

GLP-1 Receptor Agonists May Outperform Bariatric Surgery for Breast Cancer Outcomes in Obese Postmenopausal Women

By MedXY|Jun 19, 2026

In a large TriNetX study, GLP-1 receptor agonists were associated with better overall survival and lower locoregional recurrence than bariatric surgery alone in obese postmenopausal women with stage 0-III breast cancer.

GLP-1 Receptor Agonists May Outperform Bariatric Surgery in Obese Postmenopausal Breast Cancer Patients, Study Suggests
Hematology-Oncologybreast cancerobesity

GLP-1 Receptor Agonists May Outperform Bariatric Surgery in Obese Postmenopausal Breast Cancer Patients, Study Suggests

By MedXY|Aug 18, 2026

A large real-world study found GLP-1 receptor agonists were associated with better survival and lower locoregional recurrence than bariatric surgery in postmenopausal women with obesity and breast cancer.

Fovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical Trial
newsbreast cancerprogression-free survival

Fovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical Trial

By MedXY|Aug 18, 2026

Adding fovinaciclib to first-line aromatase inhibitor therapy significantly prolonged progression-free survival in advanced hormone receptor-positive, ERBB2-negative breast cancer, with manageable safety and no clear quality-of-life loss.

Impact of Population-Based Pathogenic Variant Testing on Risk-Based Breast Screening Recommendations: A Secondary Analysis of the WISDOM Study
newsbreast cancergenetic screening

Impact of Population-Based Pathogenic Variant Testing on Risk-Based Breast Screening Recommendations: A Secondary Analysis of the WISDOM Study

By MedXY|Jun 9, 2026

This WISDOM Study analysis found that most women with breast cancer pathogenic variants would not have been flagged for high-risk screening by clinical or polygenic risk models alone, supporting population-based genetic testing.

Fovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical Trial
newsbreast cancerprogression-free survival

Fovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical Trial

By MedXY|Aug 18, 2026

Adding fovinaciclib to first-line aromatase inhibitor therapy significantly prolonged progression-free survival in hormone receptor-positive, ERBB2-negative advanced breast cancer with manageable toxicity and preserved quality of life.

Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression: The BRIGHT-2 Phase 3 Randomized Clinical Trial and Comparative Synthesis
Clinical UpdatesBireociclibbreast cancer

Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression: The BRIGHT-2 Phase 3 Randomized Clinical Trial and Comparative Synthesis

By MedXY|May 26, 2026

This review synthesizes the BRIGHT-2 trial findings and meta-analytical data, confirming that bireociclib plus fulvestrant significantly improves progression-free survival in HR+/HER2- advanced breast cancer.

Survival Outcomes After Neoadjuvant Chemotherapy in Node-Positive Hormone Receptor-Positive Breast Cancer”,
General Surgerybreast cancerDi căn hạch cổ

Survival Outcomes After Neoadjuvant Chemotherapy in Node-Positive Hormone Receptor-Positive Breast Cancer”,

By MedXY|May 18, 2026

A national database study found that neoadjuvant chemotherapy was linked to worse overall survival than upfront surgery in node-positive hormone receptor-positive, HER2-negative breast cancer, except in patients who achieved nodal complete

Quality of Breast Cancer Care and Patient Survival Show No Link to Hospital Safety-Net Burden
newsbreast cancerCare Quality

Quality of Breast Cancer Care and Patient Survival Show No Link to Hospital Safety-Net Burden

By MedXY|May 1, 2026

A major study reveals that safety-net hospitals—serving vulnerable Medicaid and uninsured patients—deliver breast cancer care and survival outcomes on par with other hospitals, challenging assumptions about quality disparities in resource-c

Tamoxifen and Uterine Disease Risk in Young Breast Cancer Survivors: Evidence from a Target Trial Emulation Study
Clinical Updatesbreast cancerEndometrial Cancer

Tamoxifen and Uterine Disease Risk in Young Breast Cancer Survivors: Evidence from a Target Trial Emulation Study

By MedXY|Mar 13, 2026

A large-scale cohort study of premenopausal women demonstrates that adjuvant tamoxifen significantly increases the risk of endometrial cancer, hyperplasia, and polyps, with risk correlating to treatment duration.

Rethinking Frontline Standards: SONIA Trial Finds No Survival Benefit for First-Line CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer
newsbreast cancerCDK4/6 inhibitors

Rethinking Frontline Standards: SONIA Trial Finds No Survival Benefit for First-Line CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer

By MedXY|Mar 12, 2026

The Phase 3 SONIA trial demonstrates that delaying CDK4/6 inhibitors to the second-line setting for advanced breast cancer yields comparable overall survival to first-line use, while significantly reducing treatment-related toxicities and h

The BMPR2 Nexus: How Breast Cancer Acts as a Second Hit for Pulmonary Hypertension
Cardiologybreast cancerCardio-Oncology

The BMPR2 Nexus: How Breast Cancer Acts as a Second Hit for Pulmonary Hypertension

By MedXY|Mar 2, 2026

Emerging evidence identifies a bidirectional link between breast cancer and pulmonary arterial hypertension (PAH) driven by BMPR2 signaling and IL-1β-mediated inflammation. This study suggests breast cancer may serve as a critical second hi

Timing the Tactic: SONIA Trial Finds No Survival Advantage for First-Line vs. Second-Line CDK4/6 Inhibition in Advanced Breast Cancer
newsbreast cancerCDK4/6 inhibitors

Timing the Tactic: SONIA Trial Finds No Survival Advantage for First-Line vs. Second-Line CDK4/6 Inhibition in Advanced Breast Cancer

By MedXY|Feb 19, 2026

The phase 3 SONIA trial demonstrates that initiating CDK4/6 inhibitors in the first-line setting does not improve overall survival compared to second-line use in HR-positive, ERBB2-negative advanced breast cancer, while significantly increa

Environmental Cardiotoxicity: PM2.5 and Ozone Exposure Double the Risk of Cardiac Dysfunction in Breast Cancer Patients
Cardiologyair pollutionbreast cancer

Environmental Cardiotoxicity: PM2.5 and Ozone Exposure Double the Risk of Cardiac Dysfunction in Breast Cancer Patients

By MedXY|Feb 9, 2026

A prospective study reveals that PM2.5 and ozone exposure significantly exacerbate cardiac dysfunction and adverse remodeling in breast cancer patients receiving anthracyclines or trastuzumab, doubling the risk of clinical LVEF decline.

Mammography Screening and Mortality: A 40-Year European Population-Based Evaluation Shows Shift to Early-Stage Detection
newsbreast cancermammography

Mammography Screening and Mortality: A 40-Year European Population-Based Evaluation Shows Shift to Early-Stage Detection

By MedXY|Jan 28, 2026

A massive 21-country study confirms that mammography screening has significantly shifted breast cancer detection toward earlier stages, contributing to a substantial decline in mortality across Europe, though treatment advances also play a

Liposomal Irinotecan Offers New Hope for HER2-Negative Breast Cancer Brain Metastases: Insights from the PHENOMENAL Study
newsBrain Metastasesbreast cancer

Liposomal Irinotecan Offers New Hope for HER2-Negative Breast Cancer Brain Metastases: Insights from the PHENOMENAL Study

By MedXY|Jan 20, 2026

The PHENOMENAL phase 2 study reveals that liposomal irinotecan (nal-IRI) achieves a 22% intracranial objective response rate in patients with HER2-negative breast cancer and brain metastases, addressing a critical unmet need in neuro-oncolo

Machine Learning Accurately Predicts Distant Recurrence and Ribociclib Treatment Benefit in HR+/HER2- Early Breast Cancer
newsbreast cancermachine learning

Machine Learning Accurately Predicts Distant Recurrence and Ribociclib Treatment Benefit in HR+/HER2- Early Breast Cancer

By MedXY|Jan 13, 2026

Researchers have developed a machine learning model using real-world and clinical trial data to predict distant recurrence risk and ribociclib’s therapeutic effect in HR+/HER2- early breast cancer, offering a potential tool for person

T-DXd Combinations Redefine Therapeutic Boundaries in HER2-Low Metastatic Breast Cancer: Key Findings from DESTINY-Breast08
newsbreast cancerHER2-low

T-DXd Combinations Redefine Therapeutic Boundaries in HER2-Low Metastatic Breast Cancer: Key Findings from DESTINY-Breast08

By MedXY|Jan 13, 2026

The DESTINY-Breast08 phase 1b study demonstrates that trastuzumab deruxtecan (T-DXd) combined with chemotherapy, AKT inhibitors, or endocrine therapy is manageable and clinically active in HER2-low metastatic breast cancer, offering new pat

1 / 4
1234
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities